Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype
Randomized, Controlled, Open Label, Clinical Trial for Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in Hepatocellular Carcinoma Patients With GALNT14-rs9679162-non-TT Genotype
Sponsor: Chang Gung Memorial Hospital
Terminated
The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is required to include the patients.
Other terminated trials from Chang Gung Memorial Hospital
Other Hepatocellular Carcinoma trials with similar outcome
A PHASE2 clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Chang Gung Memorial Hospital and has accumulated 9 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chang Gung Memorial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .